BioWorld Asia

Aug. 9, 2006

Paion Accelerates Phase III Program For Desmoteplase

Paion AG is accelerating the Phase III development program for its lead compound, the recombinant plasminogen activator Desmoteplase, which is in development for treating acute ischemic stroke. (BioWorld International) Read More

Serum Institute Invests In Lipoxen; Firms Sign Deal

Neutralizing Antibody Has Promise Versus HIV Strains

Biosecurity Rises Higher Up On Europe's Agenda

Chasing Next-Generation Stents, Axordia Working With Lombard

After Knocking Out Genes, Rye Grass Pollen Made Sneeze-Free

Immutep Initiating Phase I IMP321 Breast Cancer Trial

Diamyd Medical Enters First GAD65 Out-Licensing Deal

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for June 26, 2026.

Have brain-computer interfaces finally arrived?

BioWorld

More and more individuals now have chronically implanted brain-computer interface (BCI) systems in their heads. Devices that can record and stimulate neural...

News in brief

BioWorld Asia

BioWorld Asia briefs for June 23, 2026

Brain-computer interfaces are here but long road ahead

BioWorld

The field of BCI is continually evolving; as such, companies are increasingly highlighting the potential of their technologies to transform care. For advanced...

2026 marks critical turning point for BCI technology

BioWorld

Decades of research are helping unravel the “black box” of the brain. The second article in BioWorld’s series on the Brain-Computer Interface (BCI) field looks at...